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2Abstract
The gut microbiota interact with innate immune cells and play an important role in 
shaping the immune system.  Many factors may influence the composition of the 
microbiota such as mode of birth, diet, infections and medication including antibiotics.  
In diseases with a multifactorial etiology, like type 1 diabetes, manipulation and 
alterations of the microbiota in animal models has been shown to influence the 
incidence and onset of disease.  The microbiota are an important part of the internal 
environment and understanding how these bacteria interact with the innate immune 
cells to generate immune tolerance may open up opportunities for development of new 
therapeutic strategies.  In this review, we discuss recent findings in relation to the 
microbiota, particularly in the context of type 1 diabetes.
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31. Gut microbiota and type 1 diabetes
Type 1 diabetes (T1D) is a T cell-mediated autoimmune metabolic disease which is 
commonly seen in children and young adults (1) although it can also present in older 
adults.  The insulin-producing beta cells of the pancreatic islets are damaged and 
destroyed by activated autoreactive T cells resulting in disordered blood glucose 
regulation (2).  This destruction is the result of a complex interaction between genetic 
susceptibility genes and environmental factors (3, 4). Genetic screening has shown that 
certain major histocompatibility complex (MHC) class II genes, also called human 
leukocyte antigen (HLA) genes, DQA1*0301 (DQ2), DQB1*0302 (DQ8), DRB1*DR301 
(DR3) and a number of DR4 alleles are associated with susceptibility to T1D in patients (5, 
6).  However, only a small portion of individuals carrying those alleles will develop T1D 
(7).  Yet, a sharp rise of T1D incidence has been seen in recent years (8) in a time frame 
that is not sufficient for genetic change, indicating that environmental factors may play 
a crucial role in diabetes development (9).  Prenatal influence, viral infections, dietary 
factors in the young as well as “hygiene” can all affect the disease onset (10).  More 
recently, several studies have shown commensal microbiota to be connected with the 
development of this autoimmune disease (11).  Although triggering factors for T1D 
have not yet been clearly identified, the gut microbiota are believed to play an 
important role in the development of the disease (12, 13).
The gut microbiota are associated with the development of several diseases including 
obesity and type 2 diabetes (14), liver disorders (15), intestinal inflammatory syndromes 
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4(16), allergic diseases (17), disorders in the central nervous system (18), and especially, 
autoimmune diseases (19-22).  We, and others, have recently reported that alteration 
of gut microbiota by pharmacological means can protect from or accelerate T1D 
development in non-obese diabetic (NOD) mice (23-27), a well established animal model 
for T1D research (28).
We were among the first to demonstrate that the gut microbiota shape the NOD mouse 
innate immune system (11).  MyD88 is a central adaptor in most innate immune Toll-
like receptor signaling pathways and MyD88-deficient NOD mice do not develop 
autoimmune diabetes in a clean, but not sterile, housing environment; however, germ-
free MyD88-deficient mice develop full-blown diabetes (11).  This indicates that 
commensal bacteria, especially gut bacteria play a very important role in triggering the 
autoimmune disease.  When a defined microbial mixture was introduced orally into 
the germ-free MyD88-deficient mice, diabetes development in these mice was 
attenuated (11).  Similar results were later observed in different mouse models of 
human diseases including Celiac Disease (29), obesity/type 2 diabetes (30), and 
autoimmune uveitis (31).
There are 10-fold more microorganisms residing in the gut than the total number of 
human cells (32), and they protect the host from infection by various pathogens (33).  
The main roles of gut bacteria are to aid in nutrition derived from the diet and to 
generate energy.  A healthy microbiota composition helps to keep the gut epithelia 
intact and reduce permeability (34, 35).  Furthermore, the interaction between gut 
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5epithelia and the bacteria promotes the development of a normal immune system (36, 
37).  Several reports have demonstrated that colonization by some specific bacteria in 
the gut can protect mice from developing type 1 diabetes; these bacteria include SFB 
(Segmented Filamentous Bacteria) (38), Lactobacillus johnsonii N6.2 (39), as well as 
some Streptococcal species (40), and glycoprotein extracts from Klebsiella pneumoniae 
(41).
2. Modification of the gut microbiota
Although controversial, germ-free mice (11, 42-44) may have accelerated T1D. 
Conversely, there has been speculation that gut bacteria may trigger T1D development 
in genetically susceptible humans (45) and mouse models of T1D (46).  One possible 
means by which this could occur could be transfer of metabolites or cell components of 
the bacteria through a “leaky” gut wall and uptake by antigen presenting cells, 
processing and presentation of the antigen to activate T cells (47).  Tight junctions 
represent the major barrier within the paracellular pathway between intestinal 
epithelial cells.  Alterations in intestinal permeability allow access of bacterial toxin 
(45), infectious agents and dietary antigens from the lumen to mucosal immune 
elements (48, 49).  Another possible mechanism is some bacterial product(s) share the 
molecular homology with islet autoantigen(s) and the islet beta cells are attacked by the 
immune cells that are reactive to the bactierial antigens (46).
Autoantibodies have been observed in T1D patients as young as several months old (50, 
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
651).  Animal model studies have also shown that alteration of gut microbiota early in 
life, and gut permeability are important in shaping the host immune system (25, 52, 53), 
especially at the prenatal or neonatal stages.
Efforts have been made to investigate which bacteria in the gut may be beneficial or 
harmful in the development of T1D (45, 46, 54-57).  Researchers have studied altered 
gut microbiota in experimental mice after treating with a combination of 4 antibiotics, 
including Ampicillin, Metronidazole, Neomycin and Vancomycin (58).  Although there 
are studies using germ-free (GF) mice to test whether one or more species of bacteria 
introduced into the mice has an impact on diabetes development (42, 59), which species 
are probiotic and which are detrimental have not been conclusively determined, as most 
of the bacteria in the gut are non-culturable.
Other studies have been conducted using vancomycin, a specific gram-positive bacterial 
inhibitor, to modify the gut bacteria.  Antibiotic intervention during the prenatal period 
revealed an acceleration of diabetes onset (27, 60), whereas NOD mice receiving 
vancomycin from birth onwards gave the opposite result (52).  Recently, Brown and 
colleagues showed that using Neomycin and Vancomycin to treat NOD mouse pups from 
the neonatal period for their lifetime (61) accelerated diabetes development.  These 
studies indicated that the time at which antibiotic treatment is commenced is crucial 
and that treating the mothers may be a way of having an effect while avoiding direct 
administration of the antibiotics to the pups.  Many of these studies used an approach 
giving long-term antibiotic treatment, although long-term antibiotic treatment rarely 
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7occurs in humans.  Thus, the advantage of studying short-term treatment makes the 
studies in animals closer to humans (25, 27).  In addition, human studies have shown 
that approximately 30% of pregnant women in the USA have had a short-course of 
antibiotic medication during their pregnancy (62) and the number could be higher in 
other countries.  It should be noted that long-term antibiotic treatment could cause 
resistant bacteria to propagate in the gut (63).
3. Protective bacteria that arise from pharmacological alteration of gut microbiota in 
early life.
The colonization of gut microbiota is strongly influenced by microbial exposure at birth 
(64).  When antibiotic treatment is used to study the effect of gut microbiota on 
disease, it is clear that the timing of administration, duration of treatment, as well as the 
type of antibiotic used must be taken into account.  We have published a study 
showing that Neomycin/Polymyxin B/Streptomycin- treated NOD mice were protected 
from T1D development (25).  This protection was more significant when mice were 
treated at the prenantal stage (Figure 1, adapted from reference (25))
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Figure 1: Maternal antibiotic treatment protects offspring from diabetes development in 
NOD mice.  Antibiotic treatment (3 week) starting at different times of life led to a 
different phenotype of T1D development. NPS (Neomycin/Polymyxin B/Streptomycin); 
NPS/preg (NOD offspring from mothers treated with NPS during pregnancy); NPS/born 
(NOD treated with NPS from birth to weaning); NPS/wean (NOD treated with NPS 
immediately after weaning).  The change in diabetes incidence was dependent on the 
time of antibiotic treatment.
It is clear that the earlier the NOD mice received the antibiotics, the better the 
protection from diabetes development.  In our study, NOD mice treated with NPS at 
different time points early in life delayed and overall reduced T1D onset.  When 
pregnant mothers were treated with antibiotics, the offspring were most protected 
from diabetes, while mice receiving antibiotics from birth or weaning were also 
protected from disease development although this was not statistically significant.  
Here, not only did the NPS treatment generate a gut bacterial composition that was 
protective but it was also clear that the timing of treatment was very important in 
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9inducing the effects.  Overall, these studies suggest that gut microbiota in very early 
life (prenatal or neonatal) may have the most positive impact on the host immune 
system.  Other studies have demonstrated that microbial exposure during early life is 
important for development and maintenance of the immune system and germ-free mice 
are more susceptible to developing T1D (42, 43).
Considering which bacteria have protective effects in relation to diabetes development, 
we have observed that the Gram-positive Firmucutes Lachnospiraceae and 
Coriobacteriaceae significantly increased in prenatally NPS treated mice (25).  Several 
studies in mice and human case reports indicated that, in both BioBreeding Diabetes-
Prone rats (65-67) and diabetic children (68, 69), decreased Bacteroidetes, together with 
an increase in other Gram-positive Firmicutes such as Lactobacillus, Bifidobacterium, 
were found, compared to BioBreeding Diabetes-Resistant rats and healthy children, 
respectively.
SFB (Segmented Filamentous Bacteria) are a group of bacteria within the Genus 
Candidatus Arthromitus which belongs to the Phylum of Firmicutes, Class of Clostridia 
and Family of Lachnospiraceae(70).  SFB were found to induce intestinal Th17 cells in 
Lamina Propria (LP) (71) and there are reports showing that colonization of the gut of 
NOD mice with SFB can induce a substantial population of Th17 cells in the LP and 
protect the female NOD mice from diabetes development (38).  However, we did not 
find that SFB conferred diabetes protection in NOD mice (27).  A study by Yurkovetskiy 
and colleagues also showed that SFB did not protect GF NOD mice from diabetes 
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development; however, SFB reduced T1D development in male GF NOD mice after 
colonization with other gut bacteria (72).  Since SFB are a group of bacteria, genomic 
sequencing results from several SFB strains have shown that they are different from 
each other (73-76).  It is, thereofre, conceivable that different strains may have 
different biological effects.  Nevertheless, it is still important to study the role of SFB in 
mice because these gram-positive, anaerobic, commensal bacteria are capable of 
inducing the postnatal maturation of homeostatic innate and adaptive immune 
responses in the gut.  A recent publication also showed that not only can colonization 
with SFB induce IL-17A but CXCR2-dependent recruitment of neutrophils in the gut also 
occurs (77).
4. Shaping the immune system via alterations in gut bacteria
How does alteration of the gut bacteria lead to protection from diseases like type 1 
diabetes?  There are a number of proposed mechanisms which are associated with 
genetics, gut microbiota (related to antibiotic usage, mode of delivery, diet) and 
infection in animal models and humans (78, 79).  Our recent studies indicate that 
protection can be mediated by tolerogenic antigne presenting cells (APCs) originating in 
the gut associated lymphoid tissue (GALT), which have reduced ability to stimulate 
cytotoxic CD8+ T cells. (Figure 2, Cover figure)
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Figure 2: How do antibiotics affect pancreatic beta cell autoimmunity: gut microbiota 
composition is altered after antibiotic (NPS) treatment and antigen presenting cells 
exposed to the altered bacteria in the gut display impaired antigen presenting ability to 
CD8 T cells, which in turn alleviate insulitis in the pancreas and protect the host from 
diabetes development.
In supporting the mechanism of tolerogenic APCs as a result of altered gut microbiota 
due to antibiotic usage, Umenai and coauthors showed hyporesponsiveness of 
macrophages, a potent subset of APCs, in response to LPS stimulation in mice after 
Streptomycin treatment (80).  Similarly, a recent study demonstrated that dendritic 
cells became hyporesponsive to LPS stimulation and reduced inflammatory cytokine 
production upon exposure to the gut bacterium Lactobacillus reuteri (81).  Dolpady and 
co-authors reported that administration of a mixture of Bifidobacteriaceae, 
Lactobacillaceae and Streptococcus in 4-wk old mice promoted tolerogenic CD103+ 
dendritic cells and reduced Th1 and Th17 cells in mucosal and PLN sites (82).  Thus, 
alteration of gut microbiota by different means including antibiotic treatment can  
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affect APCs lead to acceleration of or protection from diabetes development.  The 
changes in APC function could be the result of direct contact between APCs and gut 
microbiota in the gut or indirect contact, mediated by metabolites from altered gut 
microbiota.  Due to the immature nature of gut barrier and the changing, maturing 
community of gut microbiota in early-life, timing becomes critical.
Reduction in regulatory T cell markers have also been postulated as a mechanism for 
protection of NOD mice after treating with a mixture of antibiotics – metronidazole, 
streptomycin and polymyxin prenatally (53, 60).  These studies demonstrated that the 
changes in the immune system occurred when antibiotic treatment was given prenatally, 
a particularly important time for immune system development.  Livanos and coauthors 
reported recently that NOD mice receiving antibiotics (penicillin V) from lactation until 
the age of 40 days had earlier diabetes onset and overall higher incidence of diabetes 
(83).  This early-life treatment reduced the percentage of Treg and Th17 cells in lamina 
propria (LP), which may have contributed to the accelerated diabetes development.  In 
the Streptozotocin (STZ)-induced type 1 diabetes model, mice treated with antibiotics 
were fully protected from diabetes (84).  This was attributed to blocking pro-diabetic 
bacteria translocation to PLN (84).
Early-life treatment using vancomycin reduced the incidence of diabetes in one study 
(52) but accelerated diabetes in another (27).  The discrepancy may be attributed to 
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different treatment protocols.  However, the protection in Hansen’s study was 
accompanied by an increase in the level of Akkermansia, which was later reported to be 
correlated with a pro-diabetic effect (85, 86).  A gluten-free diet can also reduce 
inflammation and diabetes incidence in NOD, with elevated abundance of Akkermansia.  
Adding gluten to the gluten-free diet reversed the protection, accompanied by a 
decreased level of Akkermansia (86).  More recently, a study showed that Akkermansia 
mediate glucose tolerance via IFN (87) using loss-and-gain-of-Akkermansia muciniphila 
approaches in IFN knock-out mice.  In a clinical study, a 4-day treatment with broad-
spectrum antibiotics (Vancomycin, Gentamicin and Meropenem) significantly shifted the 
gut microbiota composition but this did not have a clinical impact in respect of 
metabolic markers such as glucose tolerance or insulin secretion (88).  However, in a 
study by Endesfelder and coauthors a change of gut microbiota occurring as a result of 
dietary change had an impact on islet autoimmunity.  The authors stratified the 
children in the study based on the microbial communities identified.  They found that it 
was possible to detect functional associations between the diet consumed, the 
microbiome and development of autoimmunity.  They identified a subgroup of 
children where Bacteroides was dominant, with low Akkermansia in the gut microbiota 
and this was associated with early introduction of a non-milk diet, lower abundance of 
genes for the production of butyrate and early autoantibody development (89, 90).   
They postulated that low butyrate generation by the bacteria contributed to increased 
risk of the development of islet autoantibodies (90).   
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It is clear that the effect of gut microbiota on host immune responses early in life is 
much stronger than later in life.  This was observed in human studies demonstrating 
that the development of type 1 diabetes was closely related to gut microbiota, gut 
permeability and immune system in early-life.  Amarri and colleagues have previously 
found that gut bacteria and gut permeability as well as other immune markers were 
significantly altered in breast-fed infants (89).  Other early influences have been 
demonstrated in a Danish study where the authors found that antibiotics used in early-
life increased the incidence of type 1 diabetes in young children: however, this was also 
related to the mode of birth delivery, which has major effects on determining the 
composition of gut microbiota at the time of birth (91).  
Antibiotic treatment in adult mice is not as effective as prenatal or neonatal treatment 
in altering the course of type 1 diabetes.  However, later life antibiotic treatment can 
significantly alter the gut bacteria and it can have clear impact on diseases other than 
T1D, including Crohn’s disease (92), colitis (93), obesity and type 2 diabetes (94).  
In addition to antibiotics, it is known that innate immune system can also alter gut 
microbiota, which affect both type 1 and type 2 diabetes development (11, 30).  
However, it was not clear which type of bacteria contribute to the protection or 
promotion of diabetes.  Using a MyD88-deficient NOD mouse that has a defined T cell 
receptor reperotire, we recently found that one type of bacterium, Leptotrichia 
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goodfellowii, in the gut can trigger diabetes development in islet-specific glucose-6-
phosphatase catalytic subunit-related protein (IGRP)-reactive CD8 T cell receptor NY8.3 
transgenic NOD model.  L. goodfellowii is a member of Fusobacteria, and expresses a 
protein peptide sharing a homologous sequence with IGRP and its abundance is 
correlated with the progression of diabetes (46).  This is the first evidence of molecular 
mimicry that relates to a bacterial antigen in initiation of diabetes onset, due to T cell 
cross-reactivity to the microbial peptide and leading to an activated autoimmune 
response.
5. Fecal microbiota transfer (FMT) as a potential therapy 
Gut bacterial composition may be altered by diet, antibiotics, probiotics, or by direct 
microbiota transfer.  Fecal microbiota transfer (FMT) has proven to be a effective way 
to transfer “healthy” microbiota, that may have beneficial effects on metabolism and 
the immune system in recipient mice (30, 95).  FMT has also been used in patients with 
colitis (96-98) and recently in cancer patients (99, 100).  We recently demonstrated 
that FMT could restore the gut microbiota and rebalance the gut hemeostasis, which in 
turns delayed diabetes onset in NOD mice (26, 29).  In other disease models, including 
obesity, the gut microbiota have been shown to contribute to generation of the 
metabolic syndrome (30).  FMT from lean mice to obese mice can ameliorate the 
metabolic syndrome in the obese mice due to the rebalancing of gut microbiota (101).  
Treating metabolic syndrome with FMT has also been tested in humans [98].  
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The beneficial effects of FMT have been particularly used in patients suffering from 
Clostridium difficile infection (102, 103).  Although antibiotic treatment has been the 
mainstay of treatment of Clostridium difficile infection, some patients have developed 
recurrent infection later on and importantly antibiotic treatment for other medical 
conditions can lead to persistent infection with Clostridium difficile (104-106).  Since 
the clinical trial on FMT in patients with recurrent Clostridium difficile infection (103), 
considerable progress has been made in this field, including formulation of the 
microbiota and delivery route of the bacteria.  Oral administration is very common 
using capsules containing the gut microbiota of healthy donors after pathogen-free 
screening, stool purification and preservation processes (107).  In addition, FMT has 
also been effective in treating diseases like ulcerative colitis (108) and chronic pouchitis 
(109) in clinical practice.  Although FMT has not been used in T1D treatment, if specific 
combinations of beneficial bacteria could be identified, this could be a promising 
therapy, given that fecal filtrate has a similar efficacy to fecal microbiota in treating 
other medical conditions (110).  However, more comprehensive studies need to be 
performed to understand which what bacterium (or bacteria) and metabolites can 
trigger the imbalance of immune system at early-life in humans at high-risk of 
developing T1D. 
6. Perspectives and conclusion
It is clear that many factors can affect the composition of gut microbiota, which 
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modulate the immune system contributing to health or disease including T1D.  Birth 
delivery mode (cesarean section vs. vaginal delivery), breast vs. formulation feeding and 
antibiotic usage, all can have a strong impact on the health of newborn infants (111-
113).  The period in utero, as well as post-partum, is a crucial time for establishment of 
the immune system of the babies.  Intervention during early life may lead to novel and 
more effective therapeutic strategies in treating T1D.  There is no doubt that gut 
microbiota are associated with particular metabolites and can influence both metabolic 
pathways and the development of the immune system.  Many studies have shown that 
depletion or alteration of intestinal microbiota has a significant impact on gut mucosal 
and epithelial gene expression, as well as immune responses (114).  Gram-negative and 
Gram-positive bacteria can stimulate different immune responses and induce Th1 or Th2 
type cytokines, as well as proinflammatory or anti-inflammatory mediators (115-118).  
We summarized some of the bacteria studied in association with T1D (Table 1).    
APC dysfunction has been found to be associated with T1D development (119, 120), but 
previously this had not been correlated with alteration of gut bacteria.  Our recent 
studies provide evidence that tolerogenic APC are generated as the results of altered gut 
microbiota (25, 27).  Interestingly, the tolerogenic APCs can confer T1D protection and 
this protection can also be transferred to a second host and to the offspring.  
Probiotics and other strategies altering the gut microbiota, including FMT, could be a 
promising approach to modulate gut microbiota and rebalance the homeostasis of 
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mucosal and systemic immune systems.  This “bug for drug” approach, also called 
“Bacteriotherapy” is being tested in different clinical trials for other medical conditions 
(121).  The prospect of this approach for T1D could be on the horizon.  Type 1 
diabetes has not only a genetically inherited component that determines susceptibility 
to disease, but the interaction with the environment to precipitate disease is a very 
important part of the pathogenesis.  Identifying modifiable environmental factors, such 
as the gut microbiota would provide a therapeutic target that could be modified by 
treatments that could be easy to administer.  It would be important to identify safe 
means of doing this that could potentially be administered very early in life.  Probiotics 
have already been tested in infants and young children but the appropriate composition 
should be identified.  Whether gut bacteria are involved in the initiation of the process 
leading to T1D or in the progression of -cell autoimmunity is still unclear (122).  A 
pure, culturable bacterial cocktail would need to be identified before this kind of 
regimen could be used in clinical practice.
A number of immunotherapeutic treatments have been trialed in human type 1 
diabetes, some of which have had a transient effect, but none as yet have been long-
lasting (123).  It has been argued that for a treatment to be successful, the innate 
immune system should present antigens in a tolerogenic manner to T regulatory cells 
(123) and this is potentially one of the ways in which altering the gut microbiota could 
work if the right combination could be identified.  Ideally, this type of treatment would 
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be combined with others that could be synergistic in maintaining a tolerogenic 
environment.
In conclusion, both probiotic and antibiotic treatment can significantly alter the gut 
bacteria, as well as the bacteria composition in other sites of the body including the oral 
cavity.  The altered bacteria interact with the host immune system and reduce 
inflammatory cytokines as well as the expression of costimlatory molecules in APCs, 
inducing a tolerogenic environment.  However, further investigation is required and, in 
particular, more work done to identify less disease- promoting gut microbiota and how 
to maintain this type of gut microbiome. 
Acknowledgements
The authors thank all the members in Wen laboratory, past and the present.  This work 
was funded by research grants from NIH (DK092882, DK100500 and P30 DK945735), 
American Diabetes Association (14-13-BS-222) and JDRF (2015-136). 
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
20
References
1. Babaya N, Nakayama M, Eisenbarth GS. The stages of type 1A diabetes. Ann N Y 
Acad Sci. 2005;1051:194-204.
2. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical 
interventions in type 1 diabetes. Nature. 2010;464(7293):1293-1300.
3. Metcalfe KA, Hitman GA, Rowe RE, Hawa M, Huang X, Stewart T, Leslie RD. 
Concordance for type 1 diabetes in identical twins is affected by insulin genotype. 
Diabetes Care. 2001;24(5):838-842.
4. Redondo MJ, Yu L, Hawa M, Mackenzie T, Pyke DA, Eisenbarth GS, Leslie RD. 
Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain 
and the United States. Diabetologia. 2001;44(3):354-362.
5. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, 
Nejentsev S, Field SF, Payne F, Lowe CE, Szeszko JS, Hafler JP, Zeitels L, Yang JH, 
Vella A, Nutland S, Stevens HE, Schuilenburg H, Coleman G, Maisuria M, 
Meadows W, Smink LJ, Healy B, Burren OS, Lam AA, Ovington NR, Allen J, Adlem 
E, Leung HT, Wallace C, Howson JM, Guja C, Ionescu-Tirgoviste C, Simmonds MJ, 
Heward JM, Gough SC, Dunger DB, Wicker LS, Clayton DG. Robust associations of 
four new chromosome regions from genome-wide analyses of type 1 diabetes. 
Nat Genet. 2007;39(7):857-864.
6. Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to susceptibility and 
resistance to insulin-dependent diabetes mellitus. Nature. 1987;329(6140):599-
604.
7. Achenbach P, Bonifacio E, Koczwara K, Ziegler AG. Natural history of type 1 
diabetes. Diabetes. 2005;54 Suppl 2:S25-31.
8. Patterson CC, Gyurus E, Rosenbauer J, Cinek O, Neu A, Schober E, Parslow RC, 
Joner G, Svensson J, Castell C, Bingley PJ, Schoenle E, Jarosz-Chobot P, Urbonaite 
B, Rothe U, Krzisnik C, Ionescu-Tirgoviste C, Weets I, Kocova M, Stipancic G, 
Samardzic M, de Beaufort CE, Green A, Dahlquist GG, Soltesz G. Trends in 
childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of 
non-uniformity over time in rates of increase. Diabetologia. 2012;55(8):2142-
2147.
9. Knip M, Veijola R, Virtanen SM, Hyoty H, Vaarala O, Akerblom HK. Environmental 
triggers and determinants of type 1 diabetes. Diabetes. 2005;54 Suppl 2:S125-
136.
10. Knip M, Simell O. Environmental triggers of type 1 diabetes. Cold Spring Harb 
Perspect Med. 2012;2(7):a007690.
11. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, 
Wong FS, Szot GL, Bluestone JA, Gordon JI, Chervonsky AV. Innate immunity and 
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
21
intestinal microbiota in the development of Type 1 diabetes. Nature. 
2008;455(7216):1109-1113.
12. Cerf-Bensussan N, Gaboriau-Routhiau V. The immune system and the gut 
microbiota: friends or foes? Nat Rev Immunol. 2010;10(10):735-744.
13. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune 
responses during health and disease. Nat Rev Immunol. 2009;9(5):313-323.
14. Tai N, Wong FS, Wen L. The role of gut microbiota in the development of type 1, 
type 2 diabetes mellitus and obesity. Rev Endocr Metab Disord. 2015;16(1):55-65.
15. Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol 
Gastroenterol Hepatol. 2015;1(3):275-284.
16. Goto Y, Kurashima Y, Kiyono H. The gut microbiota and inflammatory bowel 
disease. Curr Opin Rheumatol. 2015;27(4):388-396.
17. Vital M, Harkema JR, Rizzo M, Tiedje J, Brandenberger C. Alterations of the 
Murine Gut Microbiome with Age and Allergic Airway Disease. J Immunol Res. 
2015;2015:892568.
18. Zhao Y, Lukiw WJ. Microbiome-generated amyloid and potential impact on 
amyloidogenesis in Alzheimer's disease (AD). J Nat Sci. 2015;1(7):e138.
19. Johnson BM, Gaudreau MC, Al-Gadban MM, Gudi R, Vasu C. Impact of dietary 
deviation on disease progression and gut microbiome composition in lupus-
prone SNF1 mice. Clin Exp Immunol. 2015;181(2):323-337.
20. Verbeke KA, Boesmans L, Boets E. Modulating the microbiota in inflammatory 
bowel diseases: prebiotics, probiotics or faecal transplantation? Proc Nutr Soc. 
2014;73(4):490-497.
21. Walujkar SA, Dhotre DP, Marathe NP, Lawate PS, Bharadwaj RS, Shouche YS. 
Characterization of bacterial community shift in human Ulcerative Colitis 
patients revealed by Illumina based 16S rRNA gene amplicon sequencing. Gut 
Pathog. 2014;6:22.
22. Wu HJ, Ivanov, II, Darce J, Hattori K, Shima T, Umesaki Y, Littman DR, Benoist C, 
Mathis D. Gut-residing segmented filamentous bacteria drive autoimmune 
arthritis via T helper 17 cells. Immunity. 2010;32(6):815-827.
23. Alkanani AK, Hara N, Gottlieb PA, Ir D, Robertson CE, Wagner BD, Frank DN, 
Zipris D. Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 
1 Diabetes. Diabetes. 2015;64(10):3510-3520.
24. Burrows MP, Volchkov P, Kobayashi KS, Chervonsky AV. Microbiota regulates 
type 1 diabetes through Toll-like receptors. Proc Natl Acad Sci U S A. 
2015;112(32):9973-9977.
25. Hu Y, Peng J, Tai N, Hu C, Zhang X, Wong FS, Wen L. Maternal Antibiotic 
Treatment Protects Offspring from Diabetes Development in Nonobese Diabetic 
Mice by Generation of Tolerogenic APCs. J Immunol. 2015;195(9):4176-4184.
26. Peng J, Narasimhan S, Marchesi JR, Benson A, Wong FS, Wen L. Long term effect 
of gut microbiota transfer on diabetes development. J Autoimmun. 2014;53:85-
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
22
94.
27. Hu Y, Jin P, Peng J, Zhang X, Wong FS, Wen L. Different immunological responses 
to early-life antibiotic exposure affecting autoimmune diabetes development in 
NOD mice. J Autoimmun. 2016;72:47-56.
28. Pearson JA, Wong FS, Wen L. The importance of the Non Obese Diabetic (NOD) 
mouse model in autoimmune diabetes. J Autoimmun. 2016;66:76-88.
29. Galipeau HJ, McCarville JL, Huebener S, Litwin O, Meisel M, Jabri B, Sanz Y, 
Murray JA, Jordana M, Alaedini A, Chirdo FG, Verdu EF. Intestinal Microbiota 
Modulates Gluten-Induced Immunopathology in Humanized Mice. Am J Pathol. 
2015;185(11):2969-2982.
30. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, 
Sitaraman SV, Knight R, Ley RE, Gewirtz AT. Metabolic syndrome and altered gut 
microbiota in mice lacking Toll-like receptor 5. Science. 2010;328(5975):228-231.
31. Horai R, Zarate-Blades CR, Dillenburg-Pilla P, Chen J, Kielczewski JL, Silver PB, 
Jittayasothorn Y, Chan CC, Yamane H, Honda K, Caspi RR. Microbiota-Dependent 
Activation of an Autoreactive T Cell Receptor Provokes Autoimmunity in an 
Immunologically Privileged Site. Immunity. 2015;43(2):343-353.
32. Macpherson AJ, Uhr T. Compartmentalization of the mucosal immune responses 
to commensal intestinal bacteria. Ann N Y Acad Sci. 2004;1029:36-43.
33. Stecher B, Hardt WD. Mechanisms controlling pathogen colonization of the gut. 
Curr Opin Microbiol. 2011;14(1):82-91.
34. Natividad JM, Petit V, Huang X, de Palma G, Jury J, Sanz Y, Philpott D, Garcia 
Rodenas CL, McCoy KD, Verdu EF. Commensal and probiotic bacteria influence 
intestinal barrier function and susceptibility to colitis in Nod1-/-; Nod2-/- mice. 
Inflamm Bowel Dis. 2012;18(8):1434-1446.
35. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent 
insights and progress. Curr Gastroenterol Rep. 2010;12(5):319-330.
36. Dave M, Higgins PD, Middha S, Rioux KP. The human gut microbiome: current 
knowledge, challenges, and future directions. Transl Res. 2012;160(4):246-257.
37. Dominguez-Bello MG, Blaser MJ, Ley RE, Knight R. Development of the human 
gastrointestinal microbiota and insights from high-throughput sequencing. 
Gastroenterology. 2011;140(6):1713-1719.
38. Kriegel MA, Sefik E, Hill JA, Wu HJ, Benoist C, Mathis D. Naturally transmitted 
segmented filamentous bacteria segregate with diabetes protection in nonobese 
diabetic mice. Proc Natl Acad Sci U S A. 2011;108(28):11548-11553.
39. Lau K, Benitez P, Ardissone A, Wilson TD, Collins EL, Lorca G, Li N, Sankar D, 
Wasserfall C, Neu J, Atkinson MA, Shatz D, Triplett EW, Larkin J, 3rd. Inhibition of 
type 1 diabetes correlated to a Lactobacillus johnsonii N6.2-mediated Th17 bias. 
J Immunol. 2011;186(6):3538-3546.
40. Satoh J, Shintani S, Oya K, Tanaka S, Nobunaga T, Toyota T, Goto Y. Treatment 
with streptococcal preparation (OK-432) suppresses anti-islet autoimmunity and 
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
23
prevents diabetes in BB rats. Diabetes. 1988;37(9):1188-1194.
41. Sai P, Rivereau AS. Prevention of diabetes in the nonobese diabetic mouse by 
oral immunological treatments. Comparative efficiency of human insulin and two 
bacterial antigens, lipopolysacharide from Escherichia coli and glycoprotein 
extract from Klebsiella pneumoniae. Diabetes Metab. 1996;22(5):341-348.
42. Alam C, Bittoun E, Bhagwat D, Valkonen S, Saari A, Jaakkola U, Eerola E, 
Huovinen P, Hanninen A. Effects of a germ-free environment on gut immune 
regulation and diabetes progression in non-obese diabetic (NOD) mice. 
Diabetologia. 2011;54(6):1398-1406.
43. King C, Sarvetnick N. The incidence of type-1 diabetes in NOD mice is modulated 
by restricted flora not germ-free conditions. PLoS One. 2011;6(2):e17049.
44. Bach JF, Chatenoud L. The hygiene hypothesis: an explanation for the increased 
frequency of insulin-dependent diabetes. Cold Spring Harb Perspect Med. 
2012;2(2):a007799.
45. Vatanen T, Kostic AD, d'Hennezel E, Siljander H, Franzosa EA, Yassour M, Kolde R, 
Vlamakis H, Arthur TD, Hamalainen AM, Peet A, Tillmann V, Uibo R, Mokurov S, 
Dorshakova N, Ilonen J, Virtanen SM, Szabo SJ, Porter JA, Lahdesmaki H, 
Huttenhower C, Gevers D, Cullen TW, Knip M, Group DS, Xavier RJ. Variation in 
Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. Cell. 
2016;165(4):842-853.
46. Tai N, Peng J, Liu F, Gulden E, Hu Y, Zhang X, Chen L, Wong FS, Wen L. Microbial 
antigen mimics activate diabetogenic CD8 T cells in NOD mice. J Exp Med. 
2016;213(10):2129-2146.
47. Li X, Atkinson MA. The role for gut permeability in the pathogenesis of type 1 
diabetes - a solid or leaky concept? Pediatr Diabetes. 2015;16(7):485-492.
48. de Kort S, Keszthelyi D, Masclee AA. Leaky gut and diabetes mellitus: what is the 
link? Obes Rev. 2011;12(6):449-458.
49. Liu Z, Li N, Neu J. Tight junctions, leaky intestines, and pediatric diseases. Acta 
Paediatr. 2005;94(4):386-393.
50. Kostic AD, Gevers D, Siljander H, Vatanen T, Hyotylainen T, Hamalainen AM, Peet 
A, Tillmann V, Poho P, Mattila I, Lahdesmaki H, Franzosa EA, Vaarala O, de Goffau 
M, Harmsen H, Ilonen J, Virtanen SM, Clish CB, Oresic M, Huttenhower C, Knip M, 
Xavier RJ. The dynamics of the human infant gut microbiome in development 
and in progression toward type 1 diabetes. Cell Host Microbe. 2015;17(2):260-
273.
51. Kupila A, Muona P, Simell T, Arvilommi P, Savolainen H, Hamalainen AM, 
Korhonen S, Kimpimaki T, Sjoroos M, Ilonen J, Knip M, Simell O. Feasibility of 
genetic and immunological prediction of type I diabetes in a population-based 
birth cohort. Diabetologia. 2001;44(3):290-297.
52. Hansen CH, Krych L, Nielsen DS, Vogensen FK, Hansen LH, Sorensen SJ, Buschard 
K, Hansen AK. Early life treatment with vancomycin propagates Akkermansia 
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
24
muciniphila and reduces diabetes incidence in the NOD mouse. Diabetologia. 
2012;55(8):2285-2294.
53. Tormo-Badia N, Hakansson A, Vasudevan K, Molin G, Ahrne S, Cilio CM. 
Antibiotic treatment of pregnant non-obese diabetic mice leads to altered gut 
microbiota and intestinal immunological changes in the offspring. Scand J 
Immunol. 2014;80(4):250-260.
54. Lammi N, Karvonen M, Tuomilehto J. Do microbes have a causal role in type 1 
diabetes? Med Sci Monit. 2005;11(3):RA63-69.
55. Alyanakian MA, Grela F, Aumeunier A, Chiavaroli C, Gouarin C, Bardel E, Normier 
G, Chatenoud L, Thieblemont N, Bach JF. Transforming growth factor-beta and 
natural killer T-cells are involved in the protective effect of a bacterial extract on 
type 1 diabetes. Diabetes. 2006;55(1):179-185.
56. Korsgren S, Molin Y, Salmela K, Lundgren T, Melhus A, Korsgren O. On the 
etiology of type 1 diabetes: a new animal model signifying a decisive role for 
bacteria eliciting an adverse innate immunity response. Am J Pathol. 
2012;181(5):1735-1748.
57. Peraneva L, Fogarty CL, Pussinen PJ, Forsblom C, Groop PH, Lehto M. Systemic 
exposure to Pseudomonal bacteria: a potential link between type 1 diabetes and 
chronic inflammation. Acta Diabetol. 2013;50(3):351-361.
58. Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, Weiser JN. Recognition of 
peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. 
Nat Med. 2010;16(2):228-231.
59. Patrick C, Wang GS, Lefebvre DE, Crookshank JA, Sonier B, Eberhard C, Mojibian 
M, Kennedy CR, Brooks SP, Kalmokoff ML, Maglio M, Troncone R, Poussier P, 
Scott FW. Promotion of autoimmune diabetes by cereal diet in the presence or 
absence of microbes associated with gut immune activation, regulatory 
imbalance, and altered cathelicidin antimicrobial Peptide. Diabetes. 
2013;62(6):2036-2047.
60. Candon S, Perez-Arroyo A, Marquet C, Valette F, Foray AP, Pelletier B, Milani C, 
Ventura M, Bach JF, Chatenoud L. Antibiotics in early life alter the gut 
microbiome and increase disease incidence in a spontaneous mouse model of 
autoimmune insulin-dependent diabetes. PLoS One. 2015;10(5):e0125448.
61. Brown K, Godovannyi A, Ma C, Zhang Y, Ahmadi-Vand Z, Dai C, Gorzelak MA, 
Chan Y, Chan JM, Lochner A, Dutz JP, Vallance BA, Gibson DL. Prolonged 
antibiotic treatment induces a diabetogenic intestinal microbiome that 
accelerates diabetes in NOD mice. Isme J. 2016;10(2):321-332.
62. Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial 
medication use during pregnancy and risk of birth defects: National Birth Defects 
Prevention Study. Arch Pediatr Adolesc Med. 2009;163(11):978-985.
63. Card RM, Mafura M, Hunt T, Kirchner M, Weile J, Rashid MU, Weintraub A, Nord 
CE, Anjum MF. Impact of Ciprofloxacin and Clindamycin Administration on Gram-
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
25
Negative Bacteria Isolated from Healthy Volunteers and Characterization of the 
Resistance Genes They Harbor. Antimicrob Agents Chemother. 2015;59(8):4410-
4416.
64. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, 
Knight R. Delivery mode shapes the acquisition and structure of the initial 
microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 
2010;107(26):11971-11975.
65. Brugman S, Klatter FA, Visser JT, Wildeboer-Veloo AC, Harmsen HJ, Rozing J, Bos 
NA. Antibiotic treatment partially protects against type 1 diabetes in the Bio-
Breeding diabetes-prone rat. Is the gut flora involved in the development of type 
1 diabetes? Diabetologia. 2006;49(9):2105-2108.
66. Visser JT, Bos NA, Harthoorn LF, Stellaard F, Beijer-Liefers S, Rozing J, van Tol EA. 
Potential mechanisms explaining why hydrolyzed casein-based diets outclass 
single amino acid-based diets in the prevention of autoimmune diabetes in 
diabetes-prone BB rats. Diabetes Metab Res Rev. 2012;28(6):505-513.
67. Roesch LF, Lorca GL, Casella G, Giongo A, Naranjo A, Pionzio AM, Li N, Mai V, 
Wasserfall CH, Schatz D, Atkinson MA, Neu J, Triplett EW. Culture-independent 
identification of gut bacteria correlated with the onset of diabetes in a rat model. 
Isme J. 2009;3(5):536-548.
68. de Goffau MC, Luopajarvi K, Knip M, Ilonen J, Ruohtula T, Harkonen T, Orivuori L, 
Hakala S, Welling GW, Harmsen HJ, Vaarala O. Fecal microbiota composition 
differs between children with beta-cell autoimmunity and those without. 
Diabetes. 2013;62(4):1238-1244.
69. Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F, 
Queipo-Ortuno MI. Gut microbiota in children with type 1 diabetes differs from 
that in healthy children: a case-control study. BMC Med. 2013;11:46.
70. Thompson CL, Vier R, Mikaelyan A, Wienemann T, Brune A. 'Candidatus 
Arthromitus' revised: segmented filamentous bacteria in arthropod guts are 
members of Lachnospiraceae. Environ Microbiol. 2012;14(6):1454-1465.
71. Ivanov, II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, 
Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, 
Littman DR. Induction of intestinal Th17 cells by segmented filamentous bacteria. 
Cell. 2009;139(3):485-498.
72. Yurkovetskiy L, Burrows M, Khan AA, Graham L, Volchkov P, Becker L, 
Antonopoulos D, Umesaki Y, Chervonsky AV. Gender bias in autoimmunity is 
influenced by microbiota. Immunity. 2013;39(2):400-412.
73. Bolotin A, de Wouters T, Schnupf P, Bouchier C, Loux V, Rhimi M, Jamet A, 
Dervyn R, Boudebbouze S, Blottiere HM, Sorokin A, Snel J, Cerf-Bensussan N, 
Gaboriau-Routhiau V, van de Guchte M, Maguin E. Genome Sequence of 
"Candidatus Arthromitus" sp. Strain SFB-Mouse-NL, a Commensal Bacterium 
with a Key Role in Postnatal Maturation of Gut Immune Functions. Genome 
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
26
Announc. 2014;2(4).
74. Caselli M, Cassol F, Gentili V, Di Luca D. Genome sequences of segmented 
filamentous bacteria in animals: implications for human research. Gut Microbes. 
2012;3(5):401-405.
75. Pamp SJ, Harrington ED, Quake SR, Relman DA, Blainey PC. Single-cell sequencing 
provides clues about the host interactions of segmented filamentous bacteria 
(SFB). Genome Res. 2012;22(6):1107-1119.
76. Prakash T, Oshima K, Morita H, Fukuda S, Imaoka A, Kumar N, Sharma VK, Kim 
SW, Takahashi M, Saitou N, Taylor TD, Ohno H, Umesaki Y, Hattori M. Complete 
genome sequences of rat and mouse segmented filamentous bacteria, a potent 
inducer of th17 cell differentiation. Cell Host Microbe. 2011;10(3):273-284.
77. Flannigan KL, Ngo VL, Geem D, Harusato A, Hirota SA, Parkos CA, Lukacs NW, 
Nusrat A, Gaboriau-Routhiau V, Cerf-Bensussan N, Gewirtz AT, Denning TL. IL-
17A-mediated neutrophil recruitment limits expansion of segmented 
filamentous bacteria. Mucosal Immunol. 2016.
78. Paun A, Yau C, Danska JS. Immune recognition and response to the intestinal 
microbiome in type 1 diabetes. J Autoimmun. 2016;71:10-18.
79. Scott FW, Pound LD, Patrick C, Eberhard CE, Crookshank JA. Where genes meet 
environment-integrating the role of gut luminal contents, immunity and 
pancreas in type 1 diabetes. Transl Res. 2017;179:183-198.
80. Umenai T, Hirai H, Shime N, Nakaya T, Asahara T, Nomoto K, Kita M, Tanaka Y, 
Imanishi J. Eradication of the commensal intestinal microflora by oral 
antimicrobials interferes with the host response to lipopolysaccharide. Eur J Clin 
Microbiol Infect Dis. 2010;29(6):633-641.
81. Haileselassie Y, Navis M, Vu N, Qazi KR, Rethi B, Sverremark-Ekstrom E. 
Lactobacillus reuteri and Staphylococcus aureus differentially influence the 
generation of monocyte-derived dendritic cells and subsequent autologous T cell 
responses. Immun Inflamm Dis. 2016;4(3):315-326.
82. Dolpady J, Sorini C, Di Pietro C, Cosorich I, Ferrarese R, Saita D, Clementi M, 
Canducci F, Falcone M. Oral Probiotic VSL#3 Prevents Autoimmune Diabetes by 
Modulating Microbiota and Promoting Indoleamine 2,3-Dioxygenase-Enriched 
Tolerogenic Intestinal Environment. J Diabetes Res. 2016;2016:7569431.
83. Livanos AE, Greiner TU, Vangay P, Pathmasiri W, Stewart D, McRitchie S, Li H, 
Chung J, Sohn J, Kim S, Gao Z, Barber C, Kim J, Ng S, Rogers AB, Sumner S, Zhang 
XS, Cadwell K, Knights D, Alekseyenko A, Backhed F, Blaser MJ. Antibiotic-
mediated gut microbiome perturbation accelerates development of type 1 
diabetes in mice. Nat Microbiol. 2016;1(11):16140.
84. Costa FR, Francozo MC, de Oliveira GG, Ignacio A, Castoldi A, Zamboni DS, Ramos 
SG, Camara NO, de Zoete MR, Palm NW, Flavell RA, Silva JS, Carlos D. Gut 
microbiota translocation to the pancreatic lymph nodes triggers NOD2 activation 
and contributes to T1D onset. J Exp Med. 2016;213(7):1223-1239.
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
27
85. Hansen CH, Krych L, Buschard K, Metzdorff SB, Nellemann C, Hansen LH, Nielsen 
DS, Frokiaer H, Skov S, Hansen AK. A maternal gluten-free diet reduces 
inflammation and diabetes incidence in the offspring of NOD mice. Diabetes. 
2014;63(8):2821-2832.
86. Marietta EV, Gomez AM, Yeoman C, Tilahun AY, Clark CR, Luckey DH, Murray JA, 
White BA, Kudva YC, Rajagopalan G. Low incidence of spontaneous type 1 
diabetes in non-obese diabetic mice raised on gluten-free diets is associated with 
changes in the intestinal microbiome. PLoS One. 2013;8(11):e78687.
87. Greer RL, Dong X, Moraes AC, Zielke RA, Fernandes GR, Peremyslova E, Vasquez-
Perez S, Schoenborn AA, Gomes EP, Pereira AC, Ferreira SR, Yao M, Fuss IJ, 
Strober W, Sikora AE, Taylor GA, Gulati AS, Morgun A, Shulzhenko N. 
Akkermansia muciniphila mediates negative effects of IFNgamma on glucose 
metabolism. Nat Commun. 2016;7:13329.
88. Mikkelsen KH, Frost M, Bahl MI, Licht TR, Jensen US, Rosenberg J, Pedersen O, 
Hansen T, Rehfeld JF, Holst JJ, Vilsboll T, Knop FK. Effect of Antibiotics on Gut 
Microbiota, Gut Hormones and Glucose Metabolism. PLoS One. 
2015;10(11):e0142352.
89. Amarri S, Benatti F, Callegari ML, Shahkhalili Y, Chauffard F, Rochat F, Acheson KJ, 
Hager C, Benyacoub J, Galli E, Rebecchi A, Morelli L. Changes of gut microbiota 
and immune markers during the complementary feeding period in healthy 
breast-fed infants. J Pediatr Gastroenterol Nutr. 2006;42(5):488-495.
90. Endesfelder D, Engel M, Davis-Richardson AG, Ardissone AN, Achenbach P, 
Hummel S, Winkler C, Atkinson M, Schatz D, Triplett E, Ziegler AG, zu Castell W. 
Towards a functional hypothesis relating anti-islet cell autoimmunity to the 
dietary impact on microbial communities and butyrate production. Microbiome. 
2016;4:17.
91. Clausen TD, Bergholt T, Bouaziz O, Arpi M, Eriksson F, Rasmussen S, Keiding N, 
Lokkegaard EC. Broad-Spectrum Antibiotic Treatment and Subsequent Childhood 
Type 1 Diabetes: A Nationwide Danish Cohort Study. PLoS One. 
2016;11(8):e0161654.
92. Gevers D, Kugathasan S, Denson LA, Vazquez-Baeza Y, Van Treuren W, Ren B, 
Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, 
Gonzalez A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, 
Heyman M, Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, 
Crandall W, Hyams J, Huttenhower C, Knight R, Xavier RJ. The treatment-naive 
microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014;15(3):382-
392.
93. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier 
J, Pamer EG. Profound alterations of intestinal microbiota following a single dose 
of clindamycin results in sustained susceptibility to Clostridium difficile-induced 
colitis. Infect Immun. 2012;80(1):62-73.
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
28
94. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. 
Changes in gut microbiota control metabolic endotoxemia-induced inflammation 
in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470-
1481.
95. Markle JG, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk U, 
von Bergen M, McCoy KD, Macpherson AJ, Danska JS. Sex differences in the gut 
microbiome drive hormone-dependent regulation of autoimmunity. Science. 
2013;339(6123):1084-1088.
96. Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, Gevers D, Ting A, 
Robson SC, Moss AC. Increased Intestinal Microbial Diversity Following Fecal 
Microbiota Transplant for Active Crohn's Disease. Inflamm Bowel Dis. 
2016;22(9):2182-2190.
97. Lopez J, Grinspan A. Fecal Microbiota Transplantation for Inflammatory Bowel 
Disease. Gastroenterol Hepatol (N Y). 2016;12(6):374-379.
98. Ishikawa D, Sasaki T, Osada T, Kuwahara-Arai K, Haga K, Shibuya T, Hiramatsu K, 
Watanabe S. Changes in Intestinal Microbiota Following Combination Therapy 
with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis. 
Inflamm Bowel Dis. 2017;23(1):116-125.
99. Mittal C, Miller N, Meighani A, Hart BR, John A, Ramesh M. Fecal microbiota 
transplant for recurrent Clostridium difficile infection after peripheral autologous 
stem cell transplant for diffuse large B-cell lymphoma. Bone Marrow Transplant. 
2015;50(7):1010.
100. Blackburn LM, Bales A, Caldwell M, Cordell L, Hamilton S, Kreider H. Fecal 
microbiota transplantation in patients with cancer undergoing treatment. Clin J 
Oncol Nurs. 2015;19(1):111-114.
101. Kulecka M, Paziewska A, Zeber-Lubecka N, Ambrozkiewicz F, Kopczynski M, 
Kuklinska U, Pysniak K, Gajewska M, Mikula M, Ostrowski J. Prolonged transfer of 
feces from the lean mice modulates gut microbiota in obese mice. Nutr Metab 
(Lond). 2016;13(1):57.
102. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, Dallinga-
Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van 
Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de 
Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean 
donors increases insulin sensitivity in individuals with metabolic syndrome. 
Gastroenterology. 2012;143(4):913-916 e917.
103. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser 
CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. 
Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 
2013;368(5):407-415.
104. Girotra M, Garg S, Anand R, Song Y, Dutta SK. Fecal Microbiota Transplantation 
for Recurrent Clostridium difficile Infection in the Elderly: Long-Term Outcomes 
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
29
and Microbiota Changes. Dig Dis Sci. 2016;61(10):3007-3015.
105. Jalanka J, Mattila E, Jouhten H, Hartman J, de Vos WM, Arkkila P, Satokari R. 
Long-term effects on luminal and mucosal microbiota and commonly acquired 
taxa in faecal microbiota transplantation for recurrent Clostridium difficile 
infection. BMC Med. 2016;14(1):155.
106. Fischer M, Sipe B, Cheng YW, Phelps E, Rogers N, Sagi S, Bohm M, Xu H, Kassam Z. 
Fecal Microbiota Transplant in Severe and Severe-Complicated Clostridium 
difficile: A Promising Treatment Approach. Gut Microbes. 2016:0.
107. Hirsch BE, Saraiya N, Poeth K, Schwartz RM, Epstein ME, Honig G. Effectiveness 
of fecal-derived microbiota transfer using orally administered capsules for 
recurrent Clostridium difficile infection. BMC Infect Dis. 2015;15:191.
108. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, 
Marshall JK, Kassam Z, Reinisch W, Lee CH. Fecal Microbiota Transplantation 
Induces Remission in Patients With Active Ulcerative Colitis in a Randomized 
Controlled Trial. Gastroenterology. 2015;149(1):102-109 e106.
109. Stallmach A, Lange K, Buening J, Sina C, Vital M, Pieper DH. Fecal Microbiota 
Transfer in Patients With Chronic Antibiotic-Refractory Pouchitis. Am J 
Gastroenterol. 2016;111(3):441-443.
110. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, Cassidy L, 
Tholey A, Fickenscher H, Seegert D, Rosenstiel P, Schreiber S. Efficacy of Sterile 
Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. 
Gastroenterology. 2016;151(epub before print).
111. Rautava S. Early microbial contact, the breast milk microbiome and child health. J 
Dev Orig Health Dis. 2015:1-10.
112. Goedert JJ, Hua X, Yu G, Shi J. Diversity and composition of the adult fecal 
microbiome associated with history of cesarean birth or appendectomy: Analysis 
of the American Gut Project. EBioMedicine. 2014;1(2-3):167-172.
113. Cacho N, Neu J. Manipulation of the intestinal microbiome in newborn infants. 
Adv Nutr. 2014;5(1):114-118.
114. Reikvam DH, Erofeev A, Sandvik A, Grcic V, Jahnsen FL, Gaustad P, McCoy KD, 
Macpherson AJ, Meza-Zepeda LA, Johansen FE. Depletion of murine intestinal 
microbiota: effects on gut mucosa and epithelial gene expression. PLoS One. 
2011;6(3):e17996.
115. Tietze K, Dalpke A, Morath S, Mutters R, Heeg K, Nonnenmacher C. Differences in 
innate immune responses upon stimulation with gram-positive and gram-
negative bacteria. J Periodontal Res. 2006;41(5):447-454.
116. Dogi CA, Galdeano CM, Perdigon G. Gut immune stimulation by non pathogenic 
Gram(+) and Gram(-) bacteria. Comparison with a probiotic strain. Cytokine. 
2008;41(3):223-231.
117. Skovbjerg S, Martner A, Hynsjo L, Hessle C, Olsen I, Dewhirst FE, Tham W, Wold 
AE. Gram-positive and gram-negative bacteria induce different patterns of 
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
30
cytokine production in human mononuclear cells irrespective of taxonomic 
relatedness. J Interferon Cytokine Res. 2010;30(1):23-32.
118. De Palma G, Cinova J, Stepankova R, Tuckova L, Sanz Y. Pivotal Advance: 
Bifidobacteria and Gram-negative bacteria differentially influence immune 
responses in the proinflammatory milieu of celiac disease. J Leukoc Biol. 
2010;87(5):765-778.
119. Jin Y, Chen X, Podolsky R, Hopkins D, Makala LH, Muir A, She JX. APC dysfunction 
is correlated with defective suppression of T cell proliferation in human type 1 
diabetes. Clin Immunol. 2009;130(3):272-279.
120. Manirarora JN, Kosiewicz MM, Parnell SA, Alard P. APC activation restores 
functional CD4(+)CD25(+) regulatory T cells in NOD mice that can prevent 
diabetes development. PLoS One. 2008;3(11):e3739.
121. Patel R, DuPont HL. New approaches for bacteriotherapy: prebiotics, new-
generation probiotics, and synbiotics. Clin Infect Dis. 2015;60 Suppl 2:S108-121.
122. Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes 
mellitus. Nat Rev Endocrinol. 2016;12(3):154-167.
123. Kolb H, von Herrath M. Immunotherapy for Type 1 Diabetes: Why Do Current 
Protocols Not Halt the Underlying Disease Process? Cell Metab. 2016.
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
Table 1: Summary of bacteria studied in association with T1D 
Bacteria Gram-positive 
or -negative
Mode of action Protection from or 
acceleration of T1D
References
SFB (Segmented 
filamentous bacteria), 
Candidatus Arthromitus
positive Induce Th17 response Protection
No effect
38
27
Lactobacillus johnsonii & L. 
reuteri
positive Healthy probiotics Protection 39, 81
Klebsiella pneumoniae negative Pathogen causing pneumonia Protection 41
Bifidobacterium positive Often as healthy probiotics Acceleration 67-69
Streptococcus positive Some pathogens, some commensal 
bacteria in mouth, skin, intestine and 
upper respiratory tract
Protection 40, 82
Akkermansia muciniphila negative Mucin-degrading, often anti-inflammatory 
effect
Protection 52, 90
Bacteroides negative processing complex molecules to simpler 
compounds in the host intestine
Acceleration 89, 90
Leptotrichia goodfellowii negative Oral commensal, pathogen in immune 
compromised patients
Acceleration in NY8.3 
NOD
46
